To help reduce the burden of cardiovascular disease, the nation's leading killer, New York-Presbyterian Hospital and Weill Cornell Medical College have created the Dalio Institute of Cardiovascular Imaging. Raymond T. Dalio, a life trustee of New York-Presbyterian Hospital, has made a gift of $20 million through his Dalio Foundation in support of the institute.

The Eurozone economic slowdown has made it difficult for hospitals, particularly in Southern Europe, to procure new imaging modalities. With streamlined budgets and escalating number of medical procedures, the need to spend less on technologies while gaining the maximum benefit from them has sustained demand for high-quality refurbished imaging equipment.
cath lab radial access SCAI

The Society for Cardiovascular Angiography and Interventions (SCAI) published a first-of-its-kind paper defining best practices for the use of the transradial approach for diagnosing and treating blocked heart arteries.

InspireMD Inc., a developer of embolic protection stents, announced 12-month results from the MGuard for Acute ST Elevation Reperfusion (MASTER) trial demonstrating that the MGuard outperformed bare metal and drug-eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients.

Lantheus Medical Imaging, Inc., a developer, manufacturer and distributor of diagnostic imaging agents, announced preliminary results from the first of two planned Phase 3 trials to assess the diagnostic efficacy of flurpiridaz F 18, an imaging agent used in positron emission tomography (PET) myocardial perfusion imaging (MPI) for the detection of coronary artery disease (CAD).

Petr Neuzil, M.D., Nemocnice Na Homolce Hospital, Prague, Czech Republic, presented three-month results from the WAVE II study and complete six-month results for the WAVE I (first-in-man) at the Transcatheter Cardiovascular Therapeutics conference (TCT 2013).


No law prevents doctors from freely prescribing U.S. Food and Drug Administration (FDA)-approved drugs and devices for off-label uses, yet regulators continue to aggressively pursue civil and criminal enforcement of perceived violations, warns Patrick J. Hurd, senior counsel with LeClairRyan in Washington, D.C. and Norfolk, Va. in the November 2013 edition of Westlaw Journal Pharmaceutical.
renal denervation clinical trial study hypertension cath medtronic symplicity

Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now